Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Proof-of-concept to Evaluate the Efficacy and Safety of Prednisone in Idiosyncratic Hepatotoxicity

Phase 2

Not yet recruiting

Conditions: Hepatotoxicity
Prednisone
Idiosyncratic Drug Effect

Interventions: Drug: Prednisone

First Posted Date: 2024-02-09

Last Posted Date: 2024-04-05

Lead Sponsor: Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Target Recruit Count: 60

Registration Number: NCT06251232

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

Phase 1

Recruiting

Conditions: High Grade B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Doxorubicin
Procedure: Echocardiography
Drug: Etoposide
Procedure: Magnetic Resonance Imaging
Biological: Mosunetuzumab
Procedure: Multigated Acquisition Scan
Procedure: Positron Emission Tomography
Drug: Prednisone
Drug: Vincristine

First Posted Date: 2024-02-08

Last Posted Date: 2024-07-23

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 40

Registration Number: NCT06249191

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Selinexor, Cyclophosphamide and Prednisone in Myeloma

Phase 2

Completed

Conditions: Relapsed or Refractory Multiple Myeloma

Interventions: Drug: Selinexor
Drug: Cyclophosphamide
Drug: Prednisone

First Posted Date: 2024-01-19

Last Posted Date: 2024-01-19

Lead Sponsor: University of Leeds

Target Recruit Count: 66

Registration Number: NCT06212596

Locations: 🇬🇧
Guys and St Thomas NHS Foundation Trust, London, United Kingdom
🇬🇧
Imperial College Healthcare NHS Trust, London, United Kingdom
🇬🇧
Royal Bournemouth Hospital, Bournemouth, United Kingdom

and more 10 locations

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Phase 3

Recruiting

Conditions: Follicular Lymphoma (FL)

Interventions: Drug: Prednisone
Drug: Epcoritamab
Drug: Rituximab
Drug: Lenalidomide
Drug: Doxorubicin
Drug: Vincristine
Drug: Bendamustine
Drug: Cyclophosphamide
Drug: Obinutuzumab

First Posted Date: 2024-01-05

Last Posted Date: 2024-12-03

Lead Sponsor: Genmab

Target Recruit Count: 1080

Registration Number: NCT06191744

Locations: 🇺🇸
Rocky Mountain Cancer Centers - Boulder /ID# 261203, Boulder, Colorado, United States
🇺🇸
Christiana Care Health Service /ID# 261207, Newark, Delaware, United States
🇺🇸
Oncology Hematology Care, Inc - Blue Ash /ID# 261204, Cincinnati, Ohio, United States

and more 192 locations

Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica

Phase 3

Recruiting

Conditions: Polymyalgia Rheumatica

Interventions: Drug: Prednisone+Tofacitinib
Drug: Prednisone

First Posted Date: 2023-12-15

Last Posted Date: 2024-07-29

Lead Sponsor: Zhejiang University

Target Recruit Count: 98

Registration Number: NCT06172361

Locations: 🇨🇳
Division of Rheumatology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

Phase 2

Recruiting

Conditions: Advanced Prostate Adenocarcinoma
Stage III Prostate Cancer AJCC v8
Stage IV Prostate Cancer AJCC v8

Interventions: Drug: Abiraterone
Procedure: Biospecimen Collection
Drug: Darolutamide
Drug: Prednisone

First Posted Date: 2023-12-15

Last Posted Date: 2024-12-18

Lead Sponsor: Mamta Parikh

Target Recruit Count: 75

Registration Number: NCT06173362

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

Phase 3

Recruiting

Conditions: Chronic Graft Versus Host Disease

Interventions: Drug: Belumosudil
Drug: Placebo
Drug: Prednisone
Drug: Prednisolone

First Posted Date: 2023-11-22

Last Posted Date: 2024-12-06

Lead Sponsor: Sanofi

Target Recruit Count: 260

Registration Number: NCT06143891

Locations: 🇺🇸
Northwestern University- Site Number : 8400017, Chicago, Illinois, United States
🇺🇸
University of Kentucky Chandler Medical Center- Site Number : 8400024, Lexington, Kentucky, United States
🇺🇸
Karmanos Cancer Institute - Detroit- Site Number : 8400013, Detroit, Michigan, United States

and more 125 locations

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Phase 3

Recruiting

Conditions: Prostate Cancer Metastatic

Interventions: Drug: Opevesostat
Drug: Abiraterone acetate
Drug: Hydrocortisone
Drug: Enzalutamide
Drug: Fludrocortisone acetate
Drug: Prednisone
Drug: Dexamethasone

First Posted Date: 2023-11-18

Last Posted Date: 2024-12-09

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1200

Registration Number: NCT06136624

Locations: 🇺🇸
Stanford Cancer Center ( Site 0036), Palo Alto, California, United States
🇳🇱
Amsterdam UMC, locatie VUmc ( Site 1156), Amsterdam, Noord-Holland, Netherlands
🇵🇱
Zachodniopomorskie Centrum Onkologii ( Site 1311), Szczecin, Zachodniopomorskie, Poland

and more 242 locations